Wall Street rises as investors watch stimulus, pandemic and earnings
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
BMO Capital Reiterates Market Perform Rating on Facebook (FB) Ahead of 2Q
July 27, 2020 7:00 AM EDTBMO Capital analyst Daniel Salmon reiterated a Market Perform rating and $220.00 price target on Facebook (NASDAQ: FB) ahead of the company's 2Q earnings report. Salmon expects near-term trends to be among the strongest in BMO Capital's ad supported coverage universe and continues to believe boycotts... More
Moderna (MRNA) Initiates Phase 3 COVE Study of mRNA Vaccine Against COVID-19 (mRNA-1273)
July 27, 2020 6:53 AM EDTModerna, Inc., (NASDAQ: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the Phase 3 study of its mRNA vaccine candidate (mRNA-1273) against COVID-19 has begun dosing participants. The Phase 3 study, called the COVE (Coronavirus Efficacy) study, is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant... More
